サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
市場調査レポート
商品コード
1416208

アジア太平洋の細胞・遺伝子治療製造QC市場：分析と予測（2023年～2033年）

Asia-Pacific Cell and Gene Therapy Manufacturing QC Market: Analysis and Forecast, 2023-2033
出版日: | 発行: BIS Research | ページ情報: 英文 101 Pages | 納期: 1～5営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
アジア太平洋の細胞・遺伝子治療製造QC市場：分析と予測（2023年～2033年）
出版日: 2024年01月26日
発行: BIS Research
ページ情報: 英文 101 Pages
納期: 1～5営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要
主要市場統計
予測期間 2023年～2033年
2023年評価 4億2,630万米ドル
2033年予測 22億3,360万米ドル
CAGR 18.01%

アジア太平洋の細胞・遺伝子治療製造QCの市場規模は、2023年に4億2,630万米ドルとなりました。

同市場は、2033年には22億3,360万米ドルに達すると予測され、予測期間の2023年～2033年のCAGRは18.01%になると見込まれています。細胞・遺伝子治療製造QC（QC）市場は、承認された治療法の増加とインフラ拡充の必要性から成長が予測されます。さらに、細胞・遺伝子治療が対象とする病態が広範囲に及ぶため、大規模な製造とQCプロセスが必要となり、市場成長に寄与しています。

アジア太平洋地域では、細胞・遺伝子治療製造QC（QC）市場が著しい成長を遂げています。この市場拡大の背景には、先端療法の採用の増加、バイオテクノロジーや製薬分野への投資の増加、熟練労働力の存在など、いくつかの要因があります。さらに、同地域における慢性疾患の有病率の増加は、革新的な細胞療法や遺伝子療法の需要を加速させており、厳格なQC対策が必要とされています。新興諸国は研究開発活動に積極的に取り組んでおり、バイオテクノロジー企業との協力関係を促進しています。その結果、APACの細胞・遺伝子治療製造QC市場は今後数年間で大きく成長する見込みであり、同地域のヘルスケアソリューションの発展に貢献しています。

当レポートでは、アジア太平洋の細胞・遺伝子治療製造QC市場について調査し、市場の概要とともに、治療タイプ別、オファリング別、プロセス別、用途別、技術別、国別の動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

エグゼクティブサマリー

第1章 市場

  • 製品の定義
  • 調査手法
  • 市場概要
    • 市場シナリオ
    • 市場のフットプリントと成長の可能性
    • 将来性
    • COVID-19による市場への影響

第2章 細胞・遺伝子治療製造QC市場：業界分析

  • 規制の枠組み
    • 食品医薬品局（FDA）による化学、製造、および管理（CMC）要件
    • 欧州医薬品庁（EMA）による細胞および遺伝子治療製品の品質側面
    • 現在の適正製造基準（CGMP）規制
    • 規制の枠組み：細胞・遺伝子治療製造QC市場

第3章 細胞・遺伝子治療製造QC市場（地域別）

  • 概要
  • アジア太平洋
    • 中国
    • 日本
    • 韓国
    • オーストラリア
    • インド
    • その他の地域

第4章 企業プロファイル

図表

List of Figures

  • Figure 1: Asia-Pacific Cell and Gene Therapy Manufacturing QC Market, $Billion, 2022-2033
  • Figure 2: Asia-Pacific Cell and Gene Therapy Manufacturing QC Market, Impact Analysis
  • Figure 3: Asia-Pacific Cell and Gene Therapy Manufacturing QC Market (by Therapy Type), % Share, 2022 and 2033
  • Figure 4: Asia-Pacific Cell and Gene Therapy Manufacturing QC Market (by Offering), % Share, 2022 and 2033
  • Figure 5: Asia-Pacific Cell and Gene Therapy Manufacturing QC Market (by Process), % Share, 2022 and 2033
  • Figure 6: Asia-Pacific Cell and Gene Therapy Manufacturing QC Market (by Technology), % Share, 2022 and 2033
  • Figure 7: Asia-Pacific Cell and Gene Therapy Manufacturing QC Market (by Application), % Share, 2022 and 2033
  • Figure 8: Cell and Gene Therapy Manufacturing QC Market (by Region), Market Snapshot
  • Figure 9: Cell and Gene Therapy Manufacturing QC Market: Research Methodology
  • Figure 10: Primary Research Methodology
  • Figure 11: Bottom-Up Approach (Segment-Wise Analysis)
  • Figure 12: Top-Down Approach (Segment-Wise Analysis)
  • Figure 13: Asia-Pacific Cell and Gene Therapy Manufacturing QC Market Size and Growth Potential (Realistic Scenario), $Billion, 2022-2033
  • Figure 14: Asia-Pacific Cell and Gene Therapy Manufacturing QC Market Size and Growth Potential (Optimistic Scenario), $Billion, 2022-2033
  • Figure 15: Asia-Pacific Cell and Gene Therapy Manufacturing QC Market Size and Growth Potential (Pessimistic Scenario), $Billion, 2022-2033
  • Figure 16: Asia-Pacific Cell and Gene Therapy Manufacturing QC Market, $Billion, 2022-2033
  • Figure 17: Impact of COVID-19 on CGT Developmental Activities
  • Figure 18: Cell and Gene Therapy Manufacturing QC Market (by Region), Market Snapshot
  • Figure 19: Asia-Pacific Cell and Gene Therapy Manufacturing QC Market, $Million, 2022-2033
  • Figure 20: Asia-Pacific Cell and Gene Therapy Manufacturing QC Market (by Country), % Share, 2022-2033
  • Figure 21: Asia-Pacific Cell and Gene Therapy Manufacturing QC Market (by Offering), $Million, 2022-2033
  • Figure 22: Asia-Pacific Cell and Gene Therapy Manufacturing QC Market (by Therapy Type), $Million, 2022-2033
  • Figure 23: Asia-Pacific Cell and Gene Therapy Manufacturing QC Market (by Process), $Million, 2022-2033
  • Figure 24: Asia-Pacific Cell and Gene Therapy Manufacturing QC Market (by Technology), $Million, 2022-2033
  • Figure 25: Asia-Pacific Cell and Gene Therapy Manufacturing QC Market (by Application), $Million, 2022-2033
  • Figure 26: China Cell and Gene Therapy Manufacturing QC Market, $Million, 2022-2033
  • Figure 27: China Cell and Gene Therapy Manufacturing QC Market (by Offering), $Million, 2022-2033
  • Figure 28: China Cell and Gene Therapy Manufacturing QC Market (by Therapy Type), $Million, 2022-2033
  • Figure 29: China Cell and Gene Therapy Manufacturing QC Market (by Process), $Million, 2022-2033
  • Figure 30: China Cell and Gene Therapy Manufacturing QC Market (by Technology), $Million, 2022-2033
  • Figure 31: China Cell and Gene Therapy Manufacturing QC Market (by Application), $Million, 2022-2033
  • Figure 32: Japan Cell and Gene Therapy Manufacturing QC Market, $Million, 2022-2033
  • Figure 33: Japan Cell and Gene Therapy Manufacturing QC Market (by Offering), $Million, 2022-2033
  • Figure 34: Japan Cell and Gene Therapy Manufacturing QC Market (by Therapy Type), $Million, 2022-2033
  • Figure 35: Japan Cell and Gene Therapy Manufacturing QC Market (by Process), $Million, 2022-2033
  • Figure 36: Japan Cell and Gene Therapy Manufacturing QC Market (by Technology), $Million, 2022-2033
  • Figure 37: Japan Cell and Gene Therapy Manufacturing QC Market (by Application), $Million, 2022-2033
  • Figure 38: South Korea Cell and Gene Therapy Manufacturing QC Market, $Million, 2022-2033
  • Figure 39: South Korea Cell and Gene Therapy Manufacturing QC Market (by Offering), $Million, 2022-2033
  • Figure 40: South Korea Cell and Gene Therapy Manufacturing QC Market (by Therapy Type), $Million, 2022-2033
  • Figure 41: South Korea Cell and Gene Therapy Manufacturing QC Market (by Process), $Million, 2022-2033
  • Figure 42: South Korea Cell and Gene Therapy Manufacturing QC Market (by Technology), $Million, 2022-2033
  • Figure 43: South Korea Cell and Gene Therapy Manufacturing QC Market (by Application), $Million, 2022-2033
  • Figure 44: Australia Cell and Gene Therapy Manufacturing QC Market, $Million, 2022-2033
  • Figure 45: Australia Cell and Gene Therapy Manufacturing QC Market (by Offering), $Million, 2022-2033
  • Figure 46: Australia Cell and Gene Therapy Manufacturing QC Market (by Therapy Type), $Million, 2022-2033
  • Figure 47: Australia Cell and Gene Therapy Manufacturing QC Market (by Process), $Million, 2022-2033
  • Figure 48: Australia Cell and Gene Therapy Manufacturing QC Market (by Technology), $Million, 2022-2033
  • Figure 49: Australia Cell and Gene Therapy Manufacturing QC Market (by Application), $Million, 2022-2033
  • Figure 50: India Cell and Gene Therapy Manufacturing QC Market, $Million, 2022-2033
  • Figure 51: India Cell and Gene Therapy Manufacturing QC Market (by Offering), $Million, 2022-2033
  • Figure 52: India Cell and Gene Therapy Manufacturing QC Market (by Therapy Type), $Million, 2022-2033
  • Figure 53: India Cell and Gene Therapy Manufacturing QC Market (by Process), $Million, 2022-2033
  • Figure 54: India Cell and Gene Therapy Manufacturing QC Market (by Technology), $Million, 2022-2033
  • Figure 55: India Cell and Gene Therapy Manufacturing QC Market (by Application), $Million, 2022-2033
  • Figure 56: Rest-of-Asia-Pacific Cell and Gene Therapy Manufacturing QC Market, $Million, 2022-2033
  • Figure 57: Rest-of-Asia-Pacific Cell and Gene Therapy Manufacturing QC Market (by Offering), $Million, 2022-2033
  • Figure 58: Rest-of-Asia-Pacific Cell and Gene Therapy Manufacturing QC Market (by Therapy Type), $Million, 2022-2033
  • Figure 59: Rest-of-Asia-Pacific Cell and Gene Therapy Manufacturing QC Market (by Process), $Million, 2022-2033
  • Figure 60: Rest-of-Asia-Pacific Cell and Gene Therapy Manufacturing QC Market (by Technology), $Million, 2022-2033
  • Figure 61: Rest-of-Asia-Pacific Cell and Gene Therapy Manufacturing QC Market (by Application), $Million, 2022-2033
  • Figure 62: Total Number of Companies Profiled
  • Figure 63: WuXi AppTec: Product Portfolio
  • Figure 64: WuXi AppTec: Overall Financials, $Million, 2020-2022
  • Figure 65: WuXi AppTec: Revenue (by Segment), $Million, 2021 and 2022

List of Tables

  • Table 1: Key Questions Answered in the Report
  • Table 2: Regulatory Scenario: Cell and Gene Therapy Manufacturing QC Market
  • Table 3: Asia-Pacific Cell and Gene Therapy Manufacturing QC Market Dynamics, Impact Analysis
  • Table 4: Approved Cell and Gene Therapies, Japan
目次
Product Code: BHP1817SS

“The Asia-Pacific Cell and Gene Therapy Manufacturing QC Market Expected to Reach $2,233.6 Million by 2033.”

Introduction to Asia-Pacific Cell and Gene Therapy Manufacturing QC Market

KEY MARKET STATISTICS
Forecast Period2023 - 2033
2023 Evaluation$426.3 Million
2033 Forecast$2,233.6 Million
CAGR18.01%

The Asia-Pacific cell and gene therapy manufacturing QC market was valued at $426.3 million in 2023 and is expected to reach $2,233.6 million by 2033, growing at a CAGR of 18.01% during the forecast period 2023-2033. The cell and gene therapy manufacturing quality control (QC) market is projected to grow due to the rising number of approved therapies and the need for expanded infrastructure. Furthermore, the broader range of medical conditions targeted by cell and gene therapies necessitates large-scale manufacturing and QC processes, contributing to market growth.

Market Introduction

The Asia-Pacific (APAC) region is witnessing significant growth in the cell and gene therapy manufacturing quality control (QC) market. This expansion is driven by several factors, including the rising adoption of advanced therapies, increasing investments in biotechnology and pharmaceutical sectors, and the presence of a skilled workforce. Moreover, the growing prevalence of chronic diseases in the region has accelerated the demand for innovative cell and gene therapies, necessitating stringent QC measures. APAC countries are actively involved in research and development activities, fostering collaborations with biotech companies. As a result, the APAC cell and gene therapy manufacturing QC market is poised for substantial growth in the coming years, contributing to the advancement of healthcare solutions in the region.

Market Segmentation

Segmentation 1: by Therapy Type

  • Cell Therapy
  • Gene Therapy

Segmentation 2: by Offering

  • Products
  • Services

Segmentation 3: by Process

  • Raw Material Preparation
  • Upstream Processing
  • Downstream Processing
  • Packaging

Segmentation 4: by Application

  • Safety Testing
  • Potency Testing
  • Identity Testing
  • Stability and Genetic Fidelity Testing
  • Others

Segmentation 5: by Technology

  • Polymerase Chain Reaction (PCR)
  • Flow Cytometry
  • Limulus Amebocyte Lysate (LAL)
  • Enzyme-Linked Immunosorbent Assay (ELISA)
  • Chromatography
  • Mass Spectrometry
  • Western Blotting
  • Next-Generation Sequencing (NGS)
  • Electrophoresis
  • Other Technologies

Segmentation 6: by Country

  • China
  • Japan
  • South Korea
  • Australia
  • India
  • Rest-of-Asia-Pacific and Japan

How can this report add value to an organization?

Workflow/Innovation Strategy: The APAC cell and gene therapy manufacturing QC market (by offering) has been segmented into products and services. Moreover, the study provides the reader with a detailed understanding of the different applications of cell and gene therapy manufacturing QC in raw material preparation, upstream processing, downstream processing, and packaging.

Growth/Marketing Strategy: Cell and gene therapy manufacturing QC is being used for raw material preparation, upstream processing, downstream processing, and packaging. Various companies are providing products and services to aid in the manufacturing and QC of various cell and gene therapies, which is also the key strategy for market players to excel in the current APAC cell and gene therapy manufacturing QC market.

Competitive Strategy: Key players in the APAC cell and gene therapy manufacturing QC market have been analyzed and profiled in the study, including manufacturers involved in new product launches, acquisitions, expansions, and strategic collaborations. Moreover, a detailed competitive benchmarking of the players operating in the APAC cell and gene therapy manufacturing QC market has been done to help the reader understand how players stack against each other, presenting a clear market landscape. Additionally, comprehensive competitive strategies such as partnerships, agreements, and collaborations will aid the reader in understanding the untapped revenue pockets in the market.

Table of Contents

Executive Summary

1. Markets

  • 1.1. Product Definition
    • 1.1.1. Product Definition
    • 1.1.2. Inclusion and Exclusion Criteria
  • 1.2. Market Scope
    • 1.2.1. Key Questions Answered in the Report
  • 1.3. Research Methodology
    • 1.3.1. Cell and Gene Therapy Manufacturing QC Market
    • 1.3.2. Data Sources
      • 1.3.2.1. Primary Data Sources
      • 1.3.2.2. Secondary Data Sources
    • 1.3.3. Market Estimation Model
    • 1.3.4. Criteria for Company Profiling
  • 1.4. Market Overview
    • 1.4.1. Market Scenario
      • 1.4.1.1. Realistic Growth Scenario
      • 1.4.1.2. Optimistic Scenario
      • 1.4.1.3. Pessimistic Scenario
    • 1.4.2. Market Footprint and Growth Potential
    • 1.4.3. Future Potential
    • 1.4.4. COVID-19 Impact on Market
      • 1.4.4.1. Impact on Research and Clinical Operations
      • 1.4.4.2. COVID-19 Impact: Current Scenario of the Market
      • 1.4.4.3. Pre- and Post-COVID-19 Impact Assessment
        • 1.4.4.3.1. Pre-COVID-19 Phase
        • 1.4.4.3.2. Post-COVID-19 Phase

2. Cell and Gene Therapy Manufacturing QC Market: Industry Analysis

  • 2.1. Regulatory Framework
    • 2.1.1. Chemistry, Manufacturing, and Control (CMC) Requirements by the Food and Drug Administration (FDA)
      • 2.1.1.1. Product Testing
      • 2.1.1.2. Microbial Testing
      • 2.1.1.3. Identity
      • 2.1.1.4. Purity
      • 2.1.1.5. Potency
      • 2.1.1.6. Viability
      • 2.1.1.7. Cell Number or Dose
    • 2.1.2. Quality Aspects of Cell and Gene Therapy Products by the European Medicines Agency (EMA)
      • 2.1.2.1. Characterization
      • 2.1.2.2. Identity Testing
      • 2.1.2.3. Purity Testing
    • 2.1.3. Current Good Manufacturing Practice (CGMP) Regulations
    • 2.1.4. Regulatory Framework: Cell and Gene Therapy Manufacturing QC Market

3. Cell and Gene Therapy Manufacturing QC Market (by Region)

  • 3.1. Overview
  • 3.2. Asia-Pacific
      • 3.2.1.1. Asia-Pacific Cell and Gene Therapy Manufacturing QC Market (by Offering)
      • 3.2.1.2. Asia-Pacific Cell and Gene Therapy Manufacturing QC Market (by Therapy Type)
      • 3.2.1.3. Asia-Pacific Cell and Gene Therapy Manufacturing QC Market (by Process)
      • 3.2.1.4. Asia-Pacific Cell and Gene Therapy Manufacturing QC Market (by Technology)
      • 3.2.1.5. Asia-Pacific Cell and Gene Therapy Manufacturing QC Market (by Application)
    • 3.2.2. China
      • 3.2.2.1. China Cell and Gene Therapy Manufacturing QC Market (by Offering)
      • 3.2.2.2. China Cell and Gene Therapy Manufacturing QC Market (by Therapy Type)
      • 3.2.2.3. China Cell and Gene Therapy Manufacturing QC Market (by Process)
      • 3.2.2.4. China Cell and Gene Therapy Manufacturing QC Market (by Technology)
      • 3.2.2.5. China Cell and Gene Therapy Manufacturing QC Market (by Application)
    • 3.2.3. Japan
      • 3.2.3.1. Japan Cell and Gene Therapy Manufacturing QC Market (by Offering)
      • 3.2.3.2. Japan Cell and Gene Therapy Manufacturing QC Market (by Therapy Type)
      • 3.2.3.3. Japan Cell and Gene Therapy Manufacturing QC Market (by Process)
      • 3.2.3.4. Japan Cell and Gene Therapy Manufacturing QC Market (by Technology)
      • 3.2.3.5. Japan Cell and Gene Therapy Manufacturing QC Market (by Application)
    • 3.2.4. South Korea
      • 3.2.4.1. South Korea Cell and Gene Therapy Manufacturing QC Market (by Offering)
      • 3.2.4.2. South Korea Cell and Gene Therapy Manufacturing QC Market (by Therapy Type)
      • 3.2.4.3. South Korea Cell and Gene Therapy Manufacturing QC Market (by Process)
      • 3.2.4.4. South Korea Cell and Gene Therapy Manufacturing QC Market (by Technology)
      • 3.2.4.5. South Korea Cell and Gene Therapy Manufacturing QC Market (by Application)
    • 3.2.5. Australia
      • 3.2.5.1. Australia Cell and Gene Therapy Manufacturing QC Market (by Offering)
      • 3.2.5.2. Australia Cell and Gene Therapy Manufacturing QC Market (by Therapy Type)
      • 3.2.5.3. Australia Cell and Gene Therapy Manufacturing QC Market (by Process)
      • 3.2.5.4. Australia Cell and Gene Therapy Manufacturing QC Market (by Technology)
      • 3.2.5.5. Australia Cell and Gene Therapy Manufacturing QC Market (by Application)
    • 3.2.6. India
      • 3.2.6.1. India Cell and Gene Therapy Manufacturing QC Market (by Offering)
      • 3.2.6.2. India Cell and Gene Therapy Manufacturing QC Market (by Therapy Type)
      • 3.2.6.3. India Cell and Gene Therapy Manufacturing QC Market (by Process)
      • 3.2.6.4. India Cell and Gene Therapy Manufacturing QC Market (by Technology)
      • 3.2.6.5. India Cell and Gene Therapy Manufacturing QC Market (by Application)
    • 3.2.7. Rest-of-Asia-Pacific
      • 3.2.7.1. Rest-of-Asia-Pacific Cell and Gene Therapy Manufacturing QC Market (by Offering)
      • 3.2.7.2. Rest-of-Asia-Pacific Cell and Gene Therapy Manufacturing QC Market (by Therapy Type)
      • 3.2.7.3. Rest-of-Asia-Pacific Cell and Gene Therapy Manufacturing QC Market (by Process)
      • 3.2.7.4. Rest-of-Asia-Pacific Cell and Gene Therapy Manufacturing QC Market (by Technology)
      • 3.2.7.5. Rest-of-Asia-Pacific Cell and Gene Therapy Manufacturing QC Market (by Application)

4. Company Profiles

  • 4.1. Overview
  • 4.2. Manufacturers
    • 4.2.1. WuXi AppTec
      • 4.2.1.1. Company Overview
      • 4.2.1.2. Role of WuXi AppTec in the Cell and Gene Therapy Manufacturing QC Market
      • 4.2.1.3. Key Competitors
      • 4.2.1.4. Financials
      • 4.2.1.5. Analyst Perspective